| Biomarker ID | 1727 |
| PMID | 30516927 |
| Year | 2018 |
| Biomarker | HA: Hyaluronic acid |
| Biomarker Basis | Concentration Based (ng/mL) |
| Biomolecule | Metabolites |
| Source | Serum |
| Subjects | Humans |
| Regulation | NA |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | High Risk Vs Intermediate Risk PCa |
| Type of Biomarker | Prognostic |
| Cohort | 44 prostate cancer patients and 14 controls were used in this analysis |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.0214 |
| Method Used | fluorescence-based ELISA like assay |
| Clinical | No |
| Remarks | D’Amico’s clinical risk stratification was used to classify risk groups |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |